Article citationsMore>>

Gentileschi, S., Rigante, D., Vitale, A., Sota, J., Frediani, B., Galeazzi, M., et al. (2017) Efficacy and Safety of Anakinra in Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS) Complicated by Severe Renal Failure: A Report after Long-Term Follow-Up and Review of the Literature. Clinical Rheumatology, 36, 1687-1690.
https://doi.org/10.1007/s10067-017-3688-4

has been cited by the following article:

• TITLE: Current Indications for IL-1 Inhibition in Rheumatology

  AUTHORS: Soukaina Zaher, Kawtar Nassar, Ahlam Ajerouassi, Wafae Rachidi, Saadia Janani

  KEYWORDS: Interleukin 1, Anti-Interleukin 1, Auto-Inflammatory Disease, Anakinra, Canakinumab, Rilonacept

  JOURNAL NAME: Open Journal of Rheumatology and Autoimmune Diseases, Vol.15 No.4, November 28, 2025

  ABSTRACT: Interleukin-1 pro-inflammatory cytokines orchestrate local and systemic inflammatory responses in several diseases. Three therapeutic agents for reducing the activities of IL-1 are currently available. Conditions effectively treated with IL-1 blocking agents range from classical rheumatic diseases to autoinflammatory syndromes. In addition, IL-1 antagonism is also effective against other very common diseases, namely cardiovascular disease and type 2 diabetes, which are also co-morbidities, frequently found in patients with rheumatic diseases. Therefore, inhibition of IL-1 may provide clinical benefits beyond the efficacy of osteoarticular manifestations. The purpose of this article is to review the indications for anti-interleukins 1 in rheumatology.